James Deom, OD, MPH, FAAO, FSLS, of Hazleton Eye Specialists, explains his baseline imaging approach, his nocturnal hypotension hypothesis and his same-day workup for patients on GLP-1 RAs who have sudden vision loss.
Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.
A first-in-class small-molecule Fas inhibitor delivered by intravitreal injection is now under evaluation in more than 324 patients across North America and Europe.